Last quarter (Q4 2022), EMvision Medical Devices Ltd.'s total revenue was $―, a decrease of ― from previous quarter. In Q4, EMvision Medical Devices Ltd.'s net income was $―. See EMvision Medical Devices Ltd.’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Jun 22	Jun 21	Jun 20	Jun 19
Total Revenue	$ ―	$ ―	$ ―	$ ―	$ ―
Cost of Revenue	$ ―	$ ―	$ ―	$ ―	$ ―
Gross Profit	$ ―	$ ―	$ ―	$ ―	$ ―
Operating Expense	$ ―	$ 10.47M	$ 10.18M	$ 5.11M	$ 4.37M
Operating Income	$ ―	$ -10.47M	$ -10.18M	$ -5.11M	$ -4.37M
Net Non Operating Interest Income Expense	$ ―	$ -2.48K	$ 36.96K	$ 36.36K	$ -761.00
Other Income Expense	$ ―	$ 4.36M	$ 1.75M	$ 1.60M	$ 1.41M
Pretax Income	$ ―	$ -6.11M	$ -8.40M	$ -3.48M	$ -2.96M
Tax Provision	$ ―	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Earnings From Equity Interest Net Of Tax	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income Common Stockholders	$ ―	$ -6.11M	$ -8.40M	$ -3.48M	$ -2.96M
Basic EPS	$ ―	$ -0.08	$ -0.12	$ -0.06	$ -0.06
Diluted EPS	$ ―	$ -0.08	$ -0.12	$ -0.06	$ -0.06
Basic Average Shares	$ ―	$ 75.19M	$ 70.10M	$ 61.40M	$ 46.96M
Diluted Average Shares	$ ―	$ 75.19M	$ 70.10M	$ 61.40M	$ 46.96M
Dividend Per Share	$ ―	$ ―	$ ―	$ ―	$ ―
Total Operating Income As Reported	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Basic E P S	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Diluted E P S	$ ―	$ ―	$ ―	$ ―	$ ―
Rent Expense Supplemental	$ ―	$ ―	$ ―	$ ―	$ ―
Total Expenses	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income From Continuing And Discontinued Operation	$ ―	$ -6.11M	$ -8.40M	$ -3.48M	$ -2.96M
Normalized Income	$ ―	$ -6.11M	$ -8.40M	$ -3.48M	$ -2.96M
Interest Expense	$ ―	$ 18.12K	$ 9.84K	$ 597.00	$ 761.00
EBIT	$ ―	$ -6.09M	$ -8.39M	$ -3.48M	$ -2.96M
EBITDA	$ ―	$ -5.85M	$ -8.27M	$ -3.48M	$ -2.96M

Currency in USD

EMvision Medical Devices Ltd. Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing